Tuesday, September 1, 2026
Crinetics shareholders approve Vertex's $10 billion buyout
Crinetics Pharmaceuticals shareholders voted on August 28, 2026 to approve Vertex Pharmaceuticals' $85-per-share, roughly $10 billion cash acquisition, clearing the final outstanding condition after antitrust clearances were received in the US, Austria, Germany, and Australia. The deal, Vertex's largest ever, brings it the marketed acromegaly drug Palsonify and an endocrinology pipeline including atumelnant, with the companies now expecting the transaction to close around September 1, 2026.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.
/ Related
- Court clears Lupin's generic Kalydeco in Vertex patent fightThursday, August 27, 2026
- Rival's cystic fibrosis drug fails, Vertex shares gainThursday, August 13, 2026
- Vertex tops Q2 estimates, raises 2026 revenue guidanceTuesday, August 4, 2026
- Vertex pays AbCellera $28M upfront for autoimmune T-cell engagersFriday, July 31, 2026